Meet Reed, a man who'd trade fame for fighting cancer's darkest curse. A few years ago, we sat down with Jobs at TechCrunch Disrupt, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17 and is juggling blockbuster drugs that are all losing patent protection in roughly the same window.
This sudden shift in fortunes could be just what jobs like Reed need - a chance to make a real impact on cancer research and development. As Jobs put it, "I didn't expect Yosemite to be moving this fast." The venture outfit has been at the forefront of AI adoption, but it's clear that its latest focus is biotech.
With more time on their hands, Reed and his team are likely looking for new opportunities that leverage their expertise in AI. As Jobs noted, "AI has gone from a curiosity to, in my words, a huge part of what Yosemite does." This newfound attention to biotech could be the key to making a real difference in cancer research - and maybe even something more lucrative.